Raffi Asadorian Acelrx Pharmaceuticals Inc (ACRX) insider trading activity

Raffi Asadorian is Chief Financial Officer of ACELRX PHARMACEUTICALS INC. Currently has a direct ownership of 47,214 shares of ACRX, which is worth approximately $53,351. The most recent transaction as insider was on Apr 02, 2025, when has been sold 15,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 47.2K

25.64% 3M change

25.13% 12M change

Total Value Held $53,351

RAFFI ASADORIAN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 02 2025	BUY Grant, award, or other acquisition	-	15,000 Added 24.11%	47,214 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$2,174 $0.67 p/Share	3,245 Reduced 9.15%	32,214 Common Stock
Feb 11 2025	SELL Payment of exercise price or tax liability	$657 $0.62 p/Share	1,060 Reduced 2.9%	35,459 Common Stock
Feb 10 2025	SELL Payment of exercise price or tax liability	$667 $0.63 p/Share	1,059 Reduced 2.82%	36,519 Common Stock
Dec 02 2024	SELL Open market or private sale	$119 $0.77 p/Share	155 Reduced 0.41%	37,578 Common Stock
Mar 03 2024	SELL Payment of exercise price or tax liability	$725 $1.3 p/Share	558 Reduced 1.46%	37,733 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	18,000 Added 31.98%	38,291 Common Stock
Feb 11 2024	SELL Payment of exercise price or tax liability	$984 $1.1 p/Share	895 Reduced 4.22%	20,291 Common Stock
Feb 10 2024	SELL Payment of exercise price or tax liability	$984 $1.1 p/Share	895 Reduced 4.05%	21,186 Common Stock
Mar 03 2023	SELL Payment of exercise price or tax liability	$668 $1.31 p/Share	510 Reduced 2.26%	22,081 Common Stock
Feb 11 2023	SELL Payment of exercise price or tax liability	$1,466 $1.68 p/Share	873 Reduced 3.72%	22,591 Common Stock
Feb 10 2023	BUY Grant, award, or other acquisition	-	5,875 Added 20.02%	23,464 Common Stock
Feb 06 2023	SELL Payment of exercise price or tax liability	$1,246 $2.02 p/Share	617 Reduced 3.39%	17,589 Common Stock
Mar 03 2022	SELL Payment of exercise price or tax liability	$3,248 $0.41 p/Share	7,923 Reduced 2.13%	364,205 Common Stock
Feb 11 2022	SELL Payment of exercise price or tax liability	$3,171 $0.4 p/Share	7,927 Reduced 2.11%	368,080 Common Stock
Feb 11 2022	BUY Grant, award, or other acquisition	-	117,500 Added 23.81%	376,015 Common Stock
Feb 06 2022	SELL Payment of exercise price or tax liability	$4,038 $0.43 p/Share	9,391 Reduced 3.51%	258,515 Common Stock
Mar 03 2021	BUY Grant, award, or other acquisition	-	68,750 Added 20.87%	260,597 Common Stock
Feb 11 2021	SELL Payment of exercise price or tax liability	$23,733 $2.63 p/Share	9,024 Reduced 4.69%	183,299 Common Stock
Feb 06 2021	SELL Payment of exercise price or tax liability	$24,382 $2.59 p/Share	9,414 Reduced 4.67%	192,323 Common Stock

Raffi Asadorian

Chief Financial Officer

Redwood City, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRX shares.

Notify only if

Value

Insider Trading

Get notified when an Acelrx Pharmaceuticals Inc insider buys or sells ACRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to ACELRX PHARMACEUTICALS INC

Track Activities on ACRX

Account